Related Experiment Video

Updated: Sep 22, 2025

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
09:45

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

7.2K

KLK5 is associated with the radioresistance, aggression, and progression of cervical cancer

Shunqing Zhou1, Shuyan Liu1, Geng Tian1

  • 1Department of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun 130022, China.

Gynecologic Oncology
|May 20, 2022
PubMed
Abstract

Insights

Kallikrein-related peptidase 5 (KLK5) promotes cervical cancer's resistance to radiation therapy. Targeting KLK5 could improve treatment outcomes for patients with cervical cancer, enhancing radiosensitivity.

Area of Science:

  • Oncology
  • Biochemistry

Background:

  • Kallikrein-related peptidase 5 (KLK5) is implicated in various cancers, but its function in cervical cancer, especially concerning radiation resistance, is not well-defined.
  • Radiation resistance in cervical cancer correlates with poor prognosis, including local recurrence, metastasis, and reduced survival.

Purpose of the Study:

  • To investigate the role of KLK5 in the radioresistance and growth of cervical cancer cells.
  • To determine if KLK5 can serve as a therapeutic target or biomarker for cervical cancer radiotherapy.

Main Methods:

  • Analysis of radiotherapy-naive cervical cancer patient samples and clinical data.
  • In vitro studies using cervical cancer cell lines.
  • In vivo experiments with transplanted tumors in nude mice.

Main Results:

  • KLK5 overexpression was linked to poorer outcomes after radiotherapy in cervical cancer patients.
  • Elevated KLK5 levels significantly enhanced radiation resistance in vitro and in vivo.
  • Reducing KLK5 expression increased cervical cancer cell radiosensitivity.

Conclusions:

  • KLK5 plays a critical role in the development of radioresistance in cervical cancer.
  • KLK5 represents a promising therapeutic target and biomarker for overcoming radiation resistance in cervical cancer treatment.
Keywords:
Cervical cancerHigh-throughput sequencingKallikrein-related peptidase 5Radioresistance

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

725
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K